Autologous Tumour Vaccine Trial

A Phase I Trial of Autologous Tumour Vaccine for Advanced Solid Cancers

Phase 1 trial to evaluate the feasibility of preparation, safety, tolerability and response to a personalised autologous tumour vaccine (ATV) formulated with Advax adjuvant when administered to patients with advanced solid cancers either as monotherapy or in combination with other standard of care agents

Study Overview

• Status: Recruiting
• Conditions: Solid Tumor
• Intervention / Treatment: Biological: Radvax

Detailed Description

Radvax is a newly developed vaccine where extracted autologous tumour proteins are combined with the non-inflammatory Advax delta inulin adjuvant. Cancer immunotherapy has had a renewed interest due to the recent success and regulatory approval of immune checkpoint inhibitors and CAR-T cells. However, only a proportion of cancer patients derive benefit from these agents and hence there is an ongoing need to improve outcomes of patients with advanced solid tumours. Radvax is a novel simplified ATV approach whereby soluble tumour antigens are extracted from tumour samples obtained at surgery or from biopsy and formulated with Advax adjuvant. This vaccine has shown efficacy in murine models of glioma and pancreatic cancer, clinical trials of canine cancer patients. Radvax is now being assessed in a Phase 1 clinical trial of advanced solid cancers. Autologous tumour vaccines (ATV) will be generated from surgically removed or biopsied fresh tumour tissue. ATV is manufactured as a tumour lysate extract which is stored frozen, and then formulated with Advax adjuvant on day of administration. Doses of ATV will be administered on days 1, 8, 15, 22 during cycle 1 and then 4 weeks thereafter until total of up to 12 cycles Primary Endpoint(s): Incidence of grade 3 or 4 adverse effects Secondary Endpoint(s): Response rates by iRECIST, progression free survival and overall survival Exploratory Endpoints: To study parameters and predictive biomarkers of cancer response

• Study Type: Interventional
• Enrollment (Estimated): 30
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Sharen Pringle, GradCert; Phone Number: 0437033400; Email: office@arasmi.org

Study Locations

• Australia
  • South Australia
    • Adelaide, South Australia, Australia, 5046
      • Recruiting
      • ARASMI
      • Contact: Sharen Pringle; Phone Number: 0437033400; Email: office@arasmi.org
      • Principal Investigator: Dimitar Sajkov, MBBS/PhD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Subjects must have histologically or cytologically confirmed advanced solid cancers or hematological cancers (lymphomas only)
• Subjects must have received at least one prior therapy for this disease, with the exception that subjects for whom no standard therapy options exist or who decline standard therapies can be considered for inclusion after discussions with the investigator team.
• Performance status ≤ 2 (ECOG performance status)
• Subjects or their parents if a child must have the ability to understand and the willingness to sign a written informed consent document.
• If no suitable cancer tissue is already available to make the vaccine, to be enrolled in the trial participants must be willing to undergo surgery and/or fresh tumour biopsy to obtain tissue to allow the preparation of the vaccine and their primary care team needs to have agreed to perform these procedures for them to obtain tumour tissue. The trial team will provide advice on appropriate tissue collection and arrange transport and processing but are not responsible for arranging such surgery or paying for its cost.

Exclusion Criteria:

• Subjects receiving any other investigational agents within the preceding 4 weeks.
• Pregnant women because of the unknown risk of adverse events in the foetus secondary to treatment of the mother with ATV.
• Any potential participant where suitable cancer tissue is not available for preparation of the vaccine
• Any condition that the Investigator deems may make a potential participant unsuitable for entry into the trial.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Radvax; This is a single arm study where all participants will get active Radvax autologous tumour vaccine weekly for 4 weeks and then monthly thereafter	Biological: Radvax; Vaccine extracted from patient's own tumour tissue formulated with polysaccharide adjuvant; Other Names: Autologous tumor vaccine

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of grade 3 or 4 adverse effects	Incidence of grade 3 or 4 adverse effects related to vaccine administration	Interval from time of vaccination to 7 days post vaccination

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression free survival	Progression free survival	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months
Overall survival	Overall survival	From date of randomization to date of death from any cause, assessed up to 60 months
Response rate by RECIST version 1.1	modified Response Evaluation Criteria in Solid Tumours (RECIST version 1.1) in cancer immunotherapy trials	From date of randomization, assessed each 6 months up to 60 months

Collaborators and Investigators

• Sponsor: Vaxine Pty Ltd
• Collaborators: Australian Respiratory and Sleep Medicine Institute
• Investigators: Principal Investigator: Dimitar Sajkov, MBBS/PhD, ARASMI

Study record dates

Study Major Dates

• Study Start (Actual): February 10, 2023
• Primary Completion (Estimated): February 10, 2026
• Study Completion (Estimated): February 10, 2028

Study Registration Dates

• First Submitted: March 28, 2023
• First Submitted That Met QC Criteria: April 7, 2023
• First Posted (Actual): April 10, 2023

Study Record Updates

• Last Update Posted (Estimated): September 17, 2025
• Last Update Submitted That Met QC Criteria: September 16, 2025
• Last Verified: September 1, 2025

More Information

Terms related to this study

• Keywords: immunotherapy; cancer; vaccine; tumor; neoplasm
• Additional Relevant MeSH Terms: Neoplasms; Physiological Effects of Drugs; Immunologic Factors; FANG vaccine
• Other Study ID Numbers: CAN001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No